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Abstract
Background: Nausea is a subjective sensation which is difficult to measure in non-verbal species. The aims of this
study were to determine the efficacy of three classes of antiemetic drugs in a novel low dose cisplatin model of
nausea and vomiting and measure change in potential nausea biomarkers arginine vasopressin (AVP) and cortisol. A
four period cross-over blinded study was conducted in eight healthy beagle dogs of both genders. Dogs were
administered 18 mg/m2 cisplatin intravenously, followed 45 min later by a 15 min infusion of either placebo (saline)
or antiemetic treatment with ondansetron (0.5 mg/kg; 5-HT3 antagonist), maropitant (1 mg/kg; NK1 antagonist) or
metoclopramide (0.5 mg/kg; D2 antagonist). The number of vomits and nausea associated behaviours, scored on a
visual analogue scale, were recorded every 15 min for 8 h following cisplatin administration. Plasma samples were
collected to measure AVP, cortisol and antiemetic drug concentrations.
Results: The placebo treated group vomited an average number of 7 times (range 2–13). None of the dogs in
either the ondansetron or maropitant treated groups vomited during the observation period. The onset of nausea-
like behaviour in the placebo-treated group occurred at t3.5h and peaked at t4.75h with nausea behaviour score of
58.5 ± 4.6 mm. Ondansetron and maropitant reduced overall the area under the curve of nausea behaviour score
by 90% and 25%, respectively. Metoclopramide had no effect on either vomiting or nausea.
Cisplatin-induced nausea and vomiting caused concomitant increases in AVP and cortisol. In the placebo-treated
group, AVP and cortisol increased from t2.5h, peaked at t5h (11.3 ± 2.9 pmol L
−1 and 334.0 ± 46.7 nmol/L, respectively)
and returned to baseline by t8h. AVP and cortisol increases were completely prevented by ondansetron and only
partially by maropitant, while metoclopramide had no effect. The terminal half-lives (harmonic mean ± pseudo SD) for
ondansetron, maropitant and metoclopramide were 1.21 ± 0.51, 5.62 ± 0.77 and 0.87 ± 0.17 h respectively.
Conclusions: 5-HT3 receptor antagonist ondansetron demonstrates the greatest anti-emetic and anti-nausea efficacy
of the three drugs. AVP and cortisol appear to be selective biomarkers of nausea rather than emesis, providing a means
of objectively measuring of nausea in the dog.
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Background
Nausea is a subjective sensation induced by a variety of
emetic stimuli and usually preceeds emesis. Nausea is a
graded response with a dynamic threshold influenced by
a variety of factors [1], unlike emesis, which is an all or
nothing event occurring when emetic stimuli surpass the
threshold required to activate the emetic reflex. Defining
nausea in animals is inherently problematic due to its
subjective nature and the inability of an animal to ver-
balise the sensation that they experience. Whether or
not animals experience the sensation of nausea in the
same way as people do is a contentious issue [2]. How-
ever, for the purposes of this article the term nausea will
be used to denote the aversive state and prodromal re-
sponse induced by the administration of a known eme-
togenic substance. Nausea-like behaviour refers to
observable behaviours in animals that occur during the
aversive state.
Antiemetic drugs work by blocking the emetic path-
way at various points preventing the emetic reflex. Three
major classes of anti-emetics are currently available for
the treatment of chemotherapy-induced nausea and
vomiting: 5-hydroxytryptamine3 (5-HT3), neurokinin1
(NK1) and dopamine2 (D2) receptor antagonists. All clas-
ses of antiemetic drugs have some anti-nausea efficacy
[3–5] but are generally less efficacious for the treatment
of nausea [6]. Human patients now report that nausea
rather than emesis is the most distressing side effect of
cancer chemotherapy [7]. The sensation of nausea stems
from complex mechanisms involving cortical structures
in the forebrain responsible for conscious perception,
these mechanisms are thus far poorly characterised [8–
10]. This has hindered the development of anti-nausea
drugs.
Cisplatin is a platinum based cytotoxic drug used for
the treatment of cancer [11]. It is highly emetogenic [12]
and has been widely used experimentally to induce nau-
sea and emesis in a variety of species including Suncus
murinus [13], ferret [14] and the dog [15]. The low dose
cisplatin model of nausea and emesis in the dog [16] in-
duces significantly less emesis than previous models
which utilise clinical doses of cisplatin [15]. The reduced
emesis in the low dose model facilitates recognition of
the behavioral signs of nausea and grading of its severity
without the bias of frequent emetic events. Therefore, it
is a good model for the assessment of the anti-nausea ef-
fects of currently available anti-emetic drugs and to re-
late the concentration of nausea biomarkers to the
observed signs of nausea behaviour.
Potential nausea biomarkers, arginine vasopressin
(AVP) and cortisol, have been identified as correlates of
nausea behaviour in the dog [16]. Increased AVP has
been positively correlated to self-reported nausea scores
by volunteers, in which, motion sickness is induced
[17, 18]. To date, these biomarkers have not been
used in experimental intervention studies to assist in
objective assessment of nausea.
The principal aim of the current study was to deter-
mine the relative efficacy of the representatives of three
classes of antiemetic (ondansetron, maropitant, metoclo-
pramide) in the prevention of nausea and emesis in the
low dose cisplatin model.
Methods
Animals
Animal procedures undertaken were approved by the UK
Home Office Animals (Scientific Procedures) Act 1986
(ASPA), Project license 70/7269 with ethical approval of
the Royal Veterinary College (RVC) Ethics and Welfare
Committee. Eight healthy neutered Beagle dogs (Marshall
Farms, North Rose, NY, USA), four male and four females
weighing from 6.5 to 11.5 kg, aged 2.5 years old at the
start of the studies were used. Dogs were group-housed
according to sex on a 12 h light/dark cycle and fed canine
Lab diet 5007 (IPS Ltd., London, UK) once daily (100–
200 g adjusted as needed to maintain ideal weight). Water
was available ad libitum. The dogs were discharged from
ASPA and re-homed as pets at the end of the study with
the approval of the RVC’s Named Veterinary Surgeon.
Experimental design
Dogs received cisplatin and antiemetic or placebo treat-
ment in each of the 4 periods of the study. The 4 study
periods were blocked by sex and by day with at least a
28 day wash out period being observed between doses of
cisplatin. Antiemetic or placebo treatment was randomly
allocated during period 1 and a Latin square design was
used to determine treatment allocation in the remaining
periods so that all dogs received each treatment over the
course of the study.
Jugular vein catheter placement
One day prior to cisplatin administration, a double lumen
jugular catheter was implanted under general anesthesia
using the methods described in Kenward et al. [16].
Operator safety
Cisplatin was dispensed with the medical closed system
(BD Phaseal, Oxford, UK) under a cytotoxic hood. Ap-
propriate personal protective equipment (PPE) was worn
by users when handling cisplatin and contaminated
waste. Dogs were quarantined for 10 days following cis-
platin treatment, PPE was worn to handle dogs and all
waste was considered to be contaminated with cytotoxic
material.
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Fluid treatment
All dogs were given 0.9% saline and mannitol infusions
prior to the administration of cisplatin and an hourly sa-
line bolus post cisplatin through the first lumen of the
jugular catheter as described in Kenward et al. [16] to
reduce the nephrotoxic effects of cisplatin (Fig. 1).
Cisplatin administration
The time of initiation of cisplatin infusion was measured
in hours and defined as t0h (Fig. 1). At t0h, the dogs re-
ceived 18 mg/m2 of cisplatin (Hospira, Leamington Spa,
UK). Dogs were weighed on the day preceding the injec-
tion and body surface area (m2) calculated using the
formula:
Dose m2
  ¼ k:W
2=3
―
100
where constant k = 10.1 and W is the weight of the dog
in kilograms [19].
The appropriate volume of stock cisplatin solution
(1 mg/mL) for each dog was diluted in 0.9% saline to
produce a standard volume of 40 mL. The diluted cis-
platin solution was administered through the second
lumen of the jugular catheter using automatic dispensing
syringe at a flow rate of 2.0 mL/min.
Antiemetic administration
Anti-emetic or placebo administration was completed at
t1h following cisplatin treatment. Depending on treat-
ment allocation from the experimental design, dogs re-
ceived one of the following: 0.5 mg/kg ondansetron
(Zofran®, GSK, Brentford, UK), 1 mg/kg maropitant
(Cerenia®, Zoetis, Florham Park, NJ, USA), 0.5 mg/kg
metoclopramide (Emeprid®, Ceva Santé Animale,
Amersham, UK) or 0.9% saline as placebo. All treatments
were made up to a standard volume of 15 mL using 0.9%
saline and were administered intravenously through the
second lumen of the jugular catheter at a flow rate of
1.0 mL/min.
Behavioural assessment
Prior to the commencement of studies an acclimatization
period of 1 month was allowed for the dogs to become fa-
miliar with the experimental context. During this period,
the observer became accustomed to each individual dog’s
normal behaviour, which was used as a baseline reference
for behavioural observations. During the 28-day washout
interval between the study periods, the dogs were placed
in the experimental context weekly to prevent the devel-
opment of a conditioned response.
Observations of behaviours suggestive of a nausea-like
state and the number of vomits were recorded for 7 h
following cisplatin treatment. Nausea-like behaviour was
recorded by a single trained observer, who was blinded
to the treatment the dogs had received. A composite
‘nausea’ score was recorded using a visual analogue scale
(VAS) [15]. The observer made a judgment on the sever-
ity of the dog’s nausea-like behaviours based on the
presence and frequency of one or more of the following
during a 15 min time bin; salivation, lip licking, lethargy,
restlessness or turning/circling behaviour signaling that
vomiting is imminent. A score of 0 mm indicated ‘No
‘Nausea” and a score of 100 mm indicated ‘Worst
Fig. 1 Fluid and drug administration protocol
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possible ‘Nausea”. This method of behavioural assess-
ment in dogs was based on a ‘nausea’ visual analogue
scale described by de la Puente Redondo et al. [15] and
was validated ‘in-house’, for a cisplatin-induced nausea
and vomiting, by the authors in Kenward et al. [16].
Blood sampling
Venous blood samples were collected from the jugular
catheter for biomarker analysis at t = −3 (baseline), 0,
2.5, 4, 4.5, 5, 5.5, 6, 7, 8 and 24 h following cisplatin ad-
ministration. Additional samples were collected for
pharmacokinetic analysis of the antiemetic drugs at
t = 1.25, 1.5, 1.75, 2.25, 2.75, 3.25, 4.25, 6.25, 8.25 and
24.25 h following cisplatin administration. Approxi-
mately 5 mL of blood was collected for biomarker ana-
lysis and 0.5 mL for PK analysis at each time point,
giving a maximum of 60 mL collected per dog. Blood
was collected into EDTA coated tubes or Lithium
Heparin coated tubes as appropriate for subsequent as-
says. In agreement with ASPA regulations, a maximum
of 15% blood volume was withdrawn in any 28 day
period, with no more the 10% withdrawn in any 24 h
period. Blood sample tubes were placed in an ice bath
for a maximum of 10 min before centrifugation at 4000
x g for 15 min. Plasma samples were aliquoted into indi-
vidual tubes, A protease inhibitor cocktail (15 μM;
Sigma Aldrich, UK) was added to tubes containing
plasma for vasopressin assay. All samples were snap fro-
zen on dry ice then stored at −80 °C prior to analysis.
Biomarker measurement
Vasopressin was extracted from the plasma and the con-
centrations were measured by radioimmunoassay (RIA)
(RB-319, Eurodiagnostica AB, Malmö, Sweden), as per
kit instructions with the one adjustment that an initial
sample of 1 mL of plasma was reconstituted in 700 μL
assay buffer following solid phase extraction. This RIA
has been previously validated for use with canine plasma
[20]. Plasma cortisol concentrations were measured by
RIA (Coat-a-Count®, Siemens, Los Angeles, CA, USA),
as per kit instructions. This RIA has previously been val-
idated for use with canine plasma [21].
Pharmacokinetic analysis
Ondansetron and metoclopramide measurement
Fifty μL sample, blank, standard or quality control (QC)
were added to a 2 mL polypropylene tube. Internal
standard solution (10 μL; sulpiride) and 200 μL aceto-
nitrile (protein precipitation) were added and the tubes
were vortex mixed for 5 min. Following centrifugation at
13400 xg for 2 min, the supernatant (100 μL) was di-
luted 1:1 with de-ionised water. Ten μL of this extract
were injected onto the HPLC/MS/MS. Ondansetron and
metoclopramide concentrations were measured by
HPLC/MS/MS using a 10 cm × 4.6 mm SUPELCOSIL™
LC-Si HPLC Column maintained at 50 °C. This was
coupled with electrospray ionisation (ESI) and tandem
mass spectrometry (API 4000, Applied Biosystems). The
mobile phase consisted of acetonitrile/10 mM ammo-
nium formate (80/20 v/v) delivered at 1 mL/min. Posi-
tive ions were monitored in the MRM mode with m/z
transitions 300 → 227 for metoclopramide, 294 → 212
for ondansetron and 342 → 112 for internal standard
sulpiride. Six non-zero standards were included in each
run, final concentrations of 2.5, 10, 25, 50, 75 and
100 ng/mL in plasma. Three quality controls (15, 30 and
75 ng/mL) were also analysed in duplicate in each run.
A 1/x2 weighted linear regression was used to generate
the calibration curve for both drugs.
Maropitant measurement
Hundred μL sample, blank, standard or quality control
(QC) were added to a 96 well polypropylene plate con-
taining 400 μL acetonitrile (protein precipitation) with
5 ng/mL of internal standard CJ-12191. The plate was
sealed and centrifuged for 15 min at 1700 x g to pellet
precipitated proteins. Ten μL of supernatant was added
to a 96 well injection plate containing 790 μL water/
acetonitrile with 0.1% formic acid (50/50, v/v). Maropitant
concentrations were measured by ultra-performance li-
quid chromatography (UPLC) (Waters Acquity, Milford,
MA, USA) using Waters ACQUITY column BEH C
1.7 μm, 2.1 × 50 mm, equipped with VanGaurd ™ Pre-
Column. This was coupled with electrospray ionization
(ESI) and tandem mass spectrometry (MS/MS) (API 4000,
Applied biosystems/MDS Sciex, Frarmingham, MA,
USA). The range of the assay is 1–1000 ng/mL. The mo-
bile phase A consisted of 5 mM ammonium formate with
0.3% formic acid and mobile phase B consisted of aceto-
nitrile with 0.3% formic acid. The target column was set
to 55 °C. The UPLC was set to run a 1.8 min linear gradi-
ent initiated 0.2 min after sample injection from 10% to
99.9% mobile phase B for 2 mins. LC-MS/MS was set to
operate in positive ion mode using the ESI source. Positive
ions were monitored in the MRM mode of m/z transitions
469 → 177 for the maropitant target analyte and
455→ 163 for the internal standard CJ-12191. Eight non-
zero standards were included in each run, final concentra-
tion of 1, 2, 5, 10, 50, 100, 500 and 1000 ng/mL in dog
plasma. Three quality controls (3, 30 and 800 ng/mL)
were also analysed in duplicate in each run. A 1/x2
weighted linear regression was used to generate the cali-
bration curve.
Statistical analysis
All statistical analyses were carried out using PASW sta-
tistics 18 v 18.0.0 (SPSS: An IBM company, Chicago, IL,
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USA). All data are presented as mean ± SEM and signifi-
cance levels were set at P ≤ 0.05.
After checking normality of the distribution, correl-
ation analyses were carried out between nausea-like be-
haviour and change in biomarkers, AVP and cortisol
(Pearson’s coefficient). Time courses of nausea-like be-
haviour and change in biomarkers were analysed using a
linear mixed-effect model with 1st order autoregressive
covariance structure. The statistical model included the
fixed effects of treatment group, time and group*time
interaction, the repeated effects of time and the random
effect of subject. A least significant difference post-hoc
pairwise comparison of anti-emetic treatment was car-
ried out at each time point to determine if there was a
significant interaction between treatment and time. The
area under the curve (AUC) was calculated for time-
course of change of nausea-like behaviour and bio-
markers, AVP and cortisol, by determining the
trapezoidal area under the curve. AUCs and the differ-
ence in the number of vomits for each antiemetic treat-
ment group were compared using one-way ANOVA
with Tukeys post hoc comparison.
Pharmacokinetic parameters and compartmental mod-
elling was carried out using WinNonlin professional
software (WinNonlin, Version 5.2, Pharsight Corp,
Mountain View, CA, USA).
Results
The repeated administration of cisplatin throughout
the study was well tolerated as previously reported in
Kenward et al. [16]. Each treatment group consisted
of n = 8 except for the metoclopramide group where
n = 7 as one dog was excluded from the last period
due to the development of atopic dermatitis unrelated
to the study.
Emesis
The placebo treated group vomited an average number
of 7 times (range 2–13 vomits; Fig. 2a). None of the dogs
in either the ondansetron or maropitant treated groups
vomited during the 8 h observation period. The meto-
clopramide treated animals vomited an average of 6
times (range of 3–10 vomits). There was no statistically
significant reduction in emesis comparing the placebo
and metoclopramide treated dogs.
Signs of nausea
The onset of nausea-like behaviour in the placebo
treated group occurred at t3.5h and peaked at t4.75h with
a VAS value of 58.5 ± 4.6 mm (Fig. 2c). Nausea-like be-
haviour was significantly decreased in the ondansetron
treated group from t3.75 to 6h where the peak nausea re-
sponse was VAS 11.9 ± 7.0 mm at t4.5h (Fig. 2d). In both
the maropitant and metoclopramide treatment groups,
the onset of nausea-like behaviour was delayed. VAS
scores were significantly reduced compared to placebo
at t3.75-4h and t4.5 h in the maropitant treated group and
at t3.75-4h in the metoclopramide treated group. In the
maropitant treatment group, the peak nausea response
was 49.8 ± 7.4 mm occurring at t4.75h (Fig. 2e). The peak
nausea response for the metoclopramide treatment
group was significantly increased from placebo where
the VAS score was 72 ± 6.9 mm at t4.5h (Fig. 2f ). The
AUC for nausea-like behaviour was only significantly re-
duced in the ondansetron treated group compared pla-
cebo, a 90% reduction (Fig. 2b).
Biomarkers
Arginine vasopressin
In the placebo treated group the onset of AVP increase
occurred at t2.5h and peaked at t5h with a value of
11.35 ± 2.92 pmol/L (Fig. 3). Following cisplatin admin-
istration, the AVP concentration in the ondansetron
treated group did not exceed the baseline plasma AVP
concentration (1.11 ± 0.84 pmol/L) at any time in the
8 h following cisplatin administration and was signifi-
cantly reduced compared to placebo from t4h to t8h.
Plasma AVP was significantly decreased in the maropi-
tant treated group compared to placebo at t4.5h and t5.5h
but the peak of 9.79 ± 3.39 pmol/L was not significantly
different from placebo. No significant difference was de-
tected between the placebo and the metoclopramide
treated group at any time point during the study. The
AVP AUC of the ondansetron treated group was signifi-
cantly reduced compared to placebo (P < 0.001). There
was no significant difference in AUC between placebo
and either the maropitant or the metoclopramide treated
groups (Fig. 3).
Cortisol
Plasma cortisol increased from baseline in the placebo
treated group, the onset of increase occurred from t2.5h,
reaching a peak concentration of 334.05 ± 46.71 nmol/L
at t5h and returned to baseline by t8h (Fig. 4). The
ondansetron treated group had significantly lower corti-
sol levels compared to placebo from t4h to t5.5h. Like the
plasma AVP response, plasma cortisol of the ondanse-
tron group did not exceed mean baseline (t-3h) plasma
cortisol concentration of 87.21 ± 29.14 nmol/L at any
time following cisplatin administration. Cortisol con-
centrations were not statistically different from placebo
at any time point measured in either the maropitant
or the metoclopramide treated groups. There was no
significant difference in cortisol AUC for any of the
anti-emetic drug treatment groups compared to pla-
cebo (Fig. 4).
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Biomarkers vs nausea-like behaviour correlation
There was a weak significant correlation between AVP
and VAS (P = 0.0065, R2 = 0.1362) and between Cortisol
and VAS (P < 0.0001 and R2 = 0.2699). The relation-
ship between these variables and VAS was distorted
because of the time lag between the rise in VAS and
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Fig. 2 a-f Emesis and Nausea behaviour following 18 mg m−2 cisplatin i.v. The number of vomits (a) and area under the curve of nausea behaviour
(b) for all 3 anti-emetic drugs compared to placebo. Timecourse of nausea-like behaviour (VAS) following 18 mg m−2 cisplatin i.v. for each treatment
groups; placebo (c), ondansetron 0.5 mg kg−1 (d), maropitant 1 mg kg−1 (e), metoclopramide 0.5 mg kg−1 (f). Values presented as mean ± SEM, n = 8
per group, except metoclopramide group where n = 7. Significant decrease of antiemetic treated groups compared to placebo: mixed linear model
(**P < 0.01, *** P < 0.001), Significant increase in nausea behaviour between placebo and anti-emetic treated groups: mixed linear model (†P < 0.05).
Anti-emetic treated groups compared to placebo; Area under curve and number of vomits, ANOVA (*P < 0.05, ***P < 0.001)
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the rise of the biomarkers and can be better visua-
lised with a hysteresis plot (Fig. 5.). AVP rose with
VAS scores but persisted to high level when the nau-
sea score decreased (hysteresis loop suggesting a time
delay), whereas cortisol followed nausea scores
changes more closely in time.
Pharmacokinetics
Goodness of fit of the standard curves was R = 0.9986,
0.9863 and 0.9995 for ondansetron, maropitant and
metoclopramide, respectively. The accuracy assays
ranged between 101.3% to 108.6% for ondansetron,
82.5% to 119% for maropitant and 89.7% to 96.3% for
metoclopramide,. Plasma concentration-time profiles are
presented in Fig. 6. Disposition for all 3 antiemetic drugs
was best described by a two-compartment model. Max-
imal concentration was at the completion of the 15 min
intravenous infusion (t1h). All PK parameters are sum-
marised in Table 1.
Ondansetron concentrations in plasma were below the
lower limit of quantification in 3 of 8 dogs at t7h and in
all animals by t24h. Maropitant was still detectable in the
plasma of all dogs at t24h. Metoclopramide concentrations
in plasma fell below the lower limit of quantification in 3
of 7 dogs at t5h and in all animals at t7h.
Discussion
The present study, using a low dose model of cisplatin
to induce nausea and vomiting, has demonstrated differ-
ential relative anti-emetic and anti-nausea efficacy within
three classes of anti-emetic drugs when used at dose
rates previously shown to inhibit emesis in the dog.
Ondansetron inhibited both emesis and all behavioural
signs of nausea completely. Maropitant inhibited emesis
completely but only partially reduced the behavioural
signs of nausea at the early time points. Metoclopramide
had no significant effects on the number of episodes of
vomiting and very little effect on the behavioural signs
of nausea. These results support the hypothesis that em-
esis is easier to prevent than nausea by reducing the
neuronal signals to below the threshold required to trig-
ger emesis. By contrast, nausea, being a graded
phenomenon, persisted in the presence of concentra-
tions of maropitant which prevented dogs vomiting. The
objective biomarkers of nausea, plasma AVP and cortisol
identified by our previous characterisation of this low
dose cisplatin model [16] add weight to the conclusions
made based on subjective behavioural observations of
nausea.
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Cisplatin-induced nausea and vomiting has a biphasic
time-course in human subjects. The ‘acute’ phase of nau-
sea and vomiting occurs in the first 24 h following treat-
ment. Nausea and vomiting occurring more than 24 h
following treatment is referred to as the ‘delayed phase’
and can persist for 3–5 days [22, 23]. The present study
focused on the initial ‘acute’ phase of cisplatin-induced
nausea and vomiting which is thought to be predomin-
antly peripherally mediated. Cisplatin causes the release of
5-HT from the gut which stimulates abdominal vagal af-
ferent neurons that project to the ‘vomiting centre’ in the
brainstem [22]. Cisplatin emesis can be abolished in dogs
by abdominal vagotomy or the systemic administration of
5-HT3 antagonists but not by the central administration
of 5-HT3 antagonists into the cerebral ventricles [24]. The
‘delayed’ phase is mediated mainly by a central mechanism
of action. The area postrema (commonly referred to as
the chemoreceptor trigger zone) located in the brainstem
is thought to be stimulated by cisplatin, its metabolites, or
gut peptides released in response to the effects of cisplatin
on the intestine [22]. Ablation of the area postrema in fer-
rets abolished the delayed emetic response to cisplatin but
bilateral vagotomy did not [23].
Nausea, unlike emesis, is a multi-dimensional experi-
ence incorporating emotional and affective components in
addition to the physiological response. The sensation of
nausea is thought to arise from activation of cortical struc-
tures involved in conscious perception [9, 25, 26]. The
mechanisms by which cisplatin induces nausea are less
clear. If nausea was solely induced by stimulation of the
emetic pathways then it would be expected that abolition
of emesis would also abolish nausea, however, this is not
the case [18]. The results of the present study show, in the
maropitant treated group, that nausea-like behaviour can
be detected in the absence of an emetic response.
The low dose cisplatin model used in the present study
has greater utility for the investigation of nausea in the
dog without the large number of emetic events induced
by a clinical dose of cisplatin. A high number of emetic
events may bias the observer when judging the severity of
nausea as a function of the emesis observed rather than as
a distinct sensation with specific associated behaviours,
which may be obscured by frequent vomiting and
retching. The behavioural assessment in the present study
judged the maximum VAS score as the ‘worst possible
nausea’ for the low dose model of cisplatin gained from
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Fig. 6 Plasma concentration-time curve for the 3 antiemetic treatments. Timecourse of change in plasma concentration of the maropirant,
metoclopramide and ondansetron after intravenous injection of 1 mg kg−1, 0.5 mg kg−1 and 0.5 mg kg−1, respectively. Values presented as
mean + SEM, n = 8 per group, except metoclopramide group where n = 7
Table 1 Pharmacokinetic parameters for metoclopramide,
ondansetron and maropitant after IV administration
Parameter Units Ondansetron
(n = 8)
Maropitant
(n = 8)
Metoclopramide
(n = 7)
Cmax μg/L 186.8 ± 60.6 247.0 ± 86.2 113.2 ± 22.4
t1/2 h 1.21 ± 0.51 5.62 ± 0.77 0.87 ± 0.17
AUC0-last μg/L/h 176.4 ± 32.6 705.2 ± 236 111.9 ± 27.2
Cl L/kg/h 2.90 ± 0.43 1.57 ± 0.53 4.72 ± 1.25
MRT h 1.15 ± 0.43 6.68 ± 1.30 1.04 ± 0.16
Legend: All results are presented as the arithmetic mean ± SD except t1/2
which is presents as the harmonic mean ± Pseudo SD
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previous experience with the model [16]. This adjustment
of the behavioural scale means it is possible for a max-
imum VAS score to be given and allows for the greatest
differentiation of the anti-nausea effects of the anti-emetic
drugs tested in the model. Careful habituation of the dogs
to the context of the experiment was necessary in order
for the main investigator to learn what their normal indi-
vidual behaviour was within that situation in the absence
of cisplatin treatment.
AVP and cortisol have been previously found to be
correlates of the behavioural signs of nausea induced by
cisplatin [16] but it was not clear if the emetic response
also contributed to the change in these biomarkers. The
results of the present study support AVP and cortisol as
specific biomarkers of nausea rather than emesis.
Complete inhibition of the behavioural signs of nausea
in the ondansetron treated group results in reduction of
AVP and cortisol to baseline levels whereas complete in-
hibition of emesis and only partial inhibition of the be-
havioural aspects of the nausea in the maropitant
treated group led to only partial inhibition of AVP and
no inhibition of cortisol. AVP appears to provide the
more sensitive marker of nausea-like behaviour as partial
inhibition of nausea-like behaviour by maropitant was
identified through a significantly reduced AVP compared
to placebo at t4.5h, which was not evident in the cortisol
response. The relationship between these nausea bio-
markers and the nausea-like behavioural response re-
quires further characterisation in a study using a range
of doses of ondansetron and maropitant that describe
the full concentration anti-nausea effect relationship of
these two drugs more completely than is possible from
the data generated by the present study.
D2 receptor antagonists, such as metoclopramide, have
both central and peripheral mechanisms. They act cen-
trally on D2 receptors in emetic brainstem regions, such
as the area postrema and dorsal vagal complex [27]. Per-
ipherally, they are prokinetic, resolving gastric dysrhyth-
mias which are associated with nausea and emesis [18].
Metoclopramide also has a weak 5-HT3 antagonist ac-
tion providing some of its anti-emetic efficacy [28].
Metoclopramide has previously demonstrated some
anti-nausea efficacy in humans receiving cisplatin treat-
ment. Allan et al. [29] found that metoclopramide abol-
ished or achieved major control in 26% and 46% of
cisplatin treated patients respectively. Metoclopramide
also completely controlled nausea in 24% of patients and
achieved major control of nausea in 47% of patients; this
was increased to 32% and 62% respectively when com-
bined with dexamethasone [29]. Metoclopramide was
also found to significantly reduce the duration of nausea
induced by cisplatin chemotherapy [3]. Metoclopramide
is used frequently in veterinary medicine to control
nausea and vomiting. A dose of 1–3 mg/kg of
metoclopramide administered by subcutaneous injection
has been found to reduce cisplatin-induced emesis in
the dog [30]. However, in the current study metoclopra-
mide did not exhibit any anti-emetic or anti-nausea effi-
cacy and nausea-like behaviours actually had a higher
peak compared to placebo. One explanation for this ob-
servation could be the extra-pyramidal side effects of the
drug increasing restlessness which increased the nausea-
like behavior score above that of placebo. Metoclopra-
mide was cleared the fastest of the all three antiemetic
drugs. It is possible a higher doses of metoclopramide
may have produced a greater anti-emetic and anti-
nausea efficacy, however the administered dose of
0.5 mg/kg was at the highest end of the recommended
dose for dogs which is 0.25–0.5 mg/kg every 6–8 h [31]
and worsening extra-pyamidal side effects are seen in
dogs given high doses of metoclopramide [32].
Ondansetron was the first-in-class 5-HT3 antagonist
acting via both central and peripheral mechanisms. Per-
ipherally, 5-HT3 antagonists block the activation of ab-
dominal vagal afferents by emetic stimuli in the
gastrointestinal tract [33]. Centrally, blockade of 5-HT3
receptors on the terminals of vagal inputs into emetic
brain stem regions prevents emetic stimuli from reach-
ing the vomiting centre [28]. Ondansetron significantly
reduced the number of episodes of emesis, increased the
latency to emesis and decreased nausea VAS scores com-
pared to placebo in patients receiving cisplatin chemo-
therapy [4]. The level of control of nausea and emesis
was significantly greater with ondansetron compared to
metoclopramide and ondansetron treatment was pre-
ferred by patients [34, 35]. Ondansetron provided great-
est efficacy in the control of acute nausea following
cisplatin treatment, whereas metoclopramide was found
to be significantly more efficacious at controlling delayed
nausea [34]. The combination of ondansetron with dexa-
methasone further improved the level of control of nau-
sea [36, 37]. Ondansetron also exhibits anti-emetic and
anti-nausea efficacy in animal models of nausea and
vomiting. Ondansetron significantly inhibits emesis in-
duced by cisplatin in ferrets [38] and by methotrexate in
dogs [39]. In a lycorine model of nausea and vomiting in
beagle dogs, ondansetron significantly reduced emesis
and also exhibited significant anti-nausea activity [40].
NK1 antagonists are the most recent class of anti-
emetic drugs, aprepitant being approved by the FDA in
2003 for use in humans and maropitant being approved
in 2007 for use in the dog. The anti-emetic properties
are thought to occur as a result of the blockade of NK1
receptors in emetic brainstem regions, including the area
postrema and the nucleus tractus solitarius [41, 42]. The
addition of aprepitant to standard antiemetic therapy
with dexamethasone and a 5-HT3 antagonist improved
the control of chemotherapy-induced nausea and
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vomiting especially in the delayed phase. Aprepitant sig-
nificantly reduced emesis overall and in both the acute
and delayed phases [43–45]. Nausea was significantly re-
duced overall and in the delayed phase but not the acute
phase [43, 45]. In a clinical dose (70 mg/m2) cisplatin
model of nausea and vomiting in the dog, maropitant
significantly reduced emesis and had anti-nausea efficacy
suppressing nausea-like behaviours across the full time-
course and significantly decreasing the peak nausea re-
sponse [15]. In the present study, maropitant exhibited
less anti-nausea efficacy than reported by de la Puente
Redondo et al. [15]. It is possible that maropitant may
have greater efficacy against the more severe nausea in-
duced by the higher dose of cisplatin. For this explan-
ation to be correct would require severe nausea to be
induced by different mechanisms at higher doses of cis-
platin which seems unlikely. An alternative explanation
is that the significant reduction of emesis induced by
maropitant treatment may have caused a bias towards
reduced nausea scores in the high dose cisplatin study, a
bias that is not so much of a problem in the low dose
cisplatin model used in the present study. Another dif-
ference between the present study and that of de la
Puente Redondo et al. [15] is the route of administration
of maropitant. In the present study maropitant was ad-
ministered by i.v. infusion whereas it was given subcuta-
neously in the study by de la Puente Redondo et al. [15].
The alternative route of administration used in the
present study leads to a higher initial concentration of
maropitant and a shorter half-life compared to s.c. ad-
ministration. Maropitant plasma concentrations could
have been at sub-therapeutic concentrations during the
nausea response in the present study. However, this is
improbable as an antiemetic and anti-nausea effect dem-
onstrated 19 h following administration 1 mg/kg maro-
pitant s.c. [15] when plasma concentrations would
certainly be lower than those during the nausea response
in the present study.
The results of the present study suggest that both 5-
HT3 and NK1 receptors are an integral part of the
emetic pathway activated by cisplatin which results in
activation of the emetic reflex. The sensation of nausea
is produced in cortical forebrain regions [46], increased
activity was recorded in the left amygdala, the ventral
putamen and the putative locus coeruleus [47]. Nausio-
genic signals travel from the vomiting centre via rostrally
projecting pathways to the forebrain and nuclei control-
ling the physiological response to nausea sensation (e.g.
salivating, restlessness). The ability of ondansetron to re-
duce cisplatin-induced nausea would suggest that 5-HT3
receptors have a role in transmitting nausea stimuli, ei-
ther from the brainstem, the periphery or both, whereas
NK1 receptors are limited to a central emetic triggering
mechanism.
Conclusions
In a low dose cisplatin model of nausea and emesis in
the dog, NK1 antagonist demonstrated good anti-emetic
activity but limited anti-nausea effect. The 5-
HT3receptor antagonist ondansetron was most effective
at treating both cisplatin-induced nausea and vomiting
with associated reductions in nausea biomarkers AVP
and cortisol. Further study using escalating doses of
anti-emetics as interventions to inhibit nausea induced
by different stimuli would be beneficial to determine the
full PK/PD relationship of the anti-nausea effects of
anti-emetics and explore the utility of nausea biomarkers
in studying the pathways that can give rise to nausea.
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